FEATURES OF ANTIAGGREGATORY AND ANTI-INFLAMMATIORY EFFICACY OF ACETYLSALICYLIC ACID IN PATIENTS WITH CORONARY HEART DISEASE
Keywords:
ischemic heart disease, acetylsalicylic acid, platelet aggregation, aspirin resistance, cytokinesAbstract
Despite advances in medical science and prevention, cardiovascular pathology remains the leading cause of morbidity and mortality in economically developed countries. Acetylsalicylic acid (ASA) is currently the most widely prescribed and most proven base drug for oral antiaggregant therapy in cardiovascular disease. Despite the widespread use of acetylsalicylic acid to prevent cardiovascular complications in patients with ischemic heart disease (IHD) ischemic events also occur in a certain proportion of patients receiving regular antithrombotic therapy, which is associated with stagnation of ASA, that is seen as a manifestation of resistance. The problem of resistance to antiplatelet drugs is fundamental in its importance, as it lays the groundwork for the individualization of preventive therapy and the formation of more effective methods of disease prevention. This article discusses the problems that arise in the antiaggregant and anti-inflammatory effect of acetylsalicylic acid in the use of ischemic heart disease.
References
Androulakis, E. (2016) The impact of antiplatelet treatment on endothelial function / E. Androulakis, K Norrington, C Bakogiannis // Curr Pharm Des– 22(29) – Р. 4512-18.
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis (2015) ESC Thrombosis Working Group. // Eur Heart J. – 7;36 (46). – Р. 3238-49.
Aspirin use in patients with atherosclerotic cardiovascular disease: the 2016 Chinese expert consensus statement (2017)// Chinese Journal of Internal Medicine. –1;56(1). – Р. 68-80.
Azmin, S. (2013) Biochemical aspirin resistance in stroke patients - a cross-sectional single centre study / S. Azmin, R. Sahathevan, R. Rabani et. al. // EXCLI J. –– 12. – Р. 907-915.
Breet N.J., van Werkum J.W., Bouman II.J. et al. (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. J Am Med Assoc; 303: 754–62.
Brown G.T., McIntyre T.M. (2011) Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1β-rich microparticles. J. Immunol., Vol. 186, pp. 5489-5496.
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, (2016) // http://www.escardio.org/guidelines.
Geisler T., Zurn Ch., Simonenko R. et al. (2010) Early but not late stent thrombosis is influensed by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J; 31: 59–66.
Grove, E.L. (2017) Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs / E.L. Grove, M. Würtz //Adv Exp Med Biol.. – 906. – Р. 325-50.
Gurney, D. (2016) Platelet function testing: from routine to specialist testing / D. Gurney // Br J Biomed Sci.– 73(1). – Р. 10-20.
Hechler B., Gachet C. (2015) Purinergic receptors in thrombosis and inflammation. arterioscler. Thromb. Vasc. Biol., Vol. 35, no. 11, pp. 2307-2315.
Kaplon-Cieslicka, A. (2014) Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B2 level in aspirin-treated patients with type 2 diabetes: an observational study / A. Kaplon-Cieslicka, M. Postula, M. Rosiak // Cardiovasc Diabetol.. – 13. – Р. 112.
Lam F.W., Vijayan K.V., Rumbaut R.E. (2015) Platelets and their interactions with other immune cells. Compr. Physiol., Vol. 15, no. 3, pp. 1265-1280.
Larsen, S.B. (2015) Determinants of reduced antiplatelet effect of aspirin in patients with stable coronary artery disease / S.B. Larsen, E.L. Grove, S.D. Kristensen et al. // PLoS One.– Vol. 10, № 5. – e0126767
Oh, M.S. (2016) Aspirin resistance is associated with increased stroke severity and infarct volume / M.S. Oh, K.H. Yu, J.H. Lee et. al. // Neurology.. – 86 (19). – Р. 1808-17.
Panoulas V.F., Stavropoulos-Kalinoglou A., Metsios G.S. et al. (2009) Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking. Atherosclerosis; 204(1):178–83.
Sibbing D., Morath T., Braun S. et al. (2010) Clopidogrel response status assessed with Multiplate point-of care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost; 103: 151–59.
Tsau, S. (2015) Aspirin and multiple sclerosis / S. Tsau, M.R. Emerson, S.G. Lynch et al. // BMC Med.– 13. – Р. 153.
Yildiz B.S. (2016) Does high serum uric acid level cause aspirin resistance? / B.S. Yildiz, E Ozkan, F. Esin // Blood Coagul Fibrinolysis.– 27(4). – Р. 412-18.
Borovkov N.N. (2014) Atsetilsalitsilovaya kislota ostayetsya «zolotym standartom antiagregantnoy terapii stabil'noy stenokardii / Borovkov N.N., BorovkovaN.YU. // Spravochnik poliklinicheskogo vracha. -№ 2. -S. 26-28.
Vorob'yova N.M. (2014) Nekotoriye aspekti primeneniya atsetilsalitsilovoy kisloty i klopidogrela u kardiologicheskix bol'nix / Vorob'yova N.M. //Lechashiy vrach. - № 7.- S. 20.
Dobrovol'skiy, A. B. (2015) Laboratornaya diagnostika narusheniy sistemi gemostaza - skriningoviye testi / A. B. Dobrovol'skiy // Rossiyskiy kardiologicheskiy jurnal.– № 3 (119). – S. 52-57.
Domashenko M.A. (2014) Algoritm antitromboticheskoy terapii u patsiyentov s ishemicheskim insul'tom posle sistemnogo trombolizisa / Domashenko M.A., Maksimova M.YU., Tanashyan M.M. // Meditsinskiy sovet. № 7. S. 39-42.
Komarov, A.L. (2015) Testirovaniye funktsii trombotsitov dlya otsenki riska trombozov i krovotecheniy u bol'nix IBS, poluchayushix antiagreganti / A.L. Komarov, Ye.P. Panchenko // Rossiyskiy kardiologicheskiy zhurnal.– 3 (119). – S. 25-34.
Laguta P.S. (2014) Primeneniye atsetilsalitsilovoy kisloty u kardiologicheskix bol'nix: sushestvuyushiye problemi i noviye pokazaniya / P.S. Laguta// Aterotromboz. № 1. S. 5-21.
Mazur, N.A. (2016) Dezagregantnaya terapiya u bol'nix ishemicheskoy bolezn'yu serdtsa: nereshenniye problemi / N.A. Mazur // Kardiologiya. – T. 56, № 1. – S. 66-70.
Minushkina L.O. (2014) Problemy bezopasnosti pri ispol'zovanii preparatov atsetilsalitsilovoy kisloty dlya profilaktiki serdechno-sosudistix oslojneniy / Minushkina L.O. // Lechashiy vrach. № 4. S. 80.
Nikolenko, L.A. (2015) Agregatsionnaya aktivnost' trombotsitov i effektivnost' antitromboticheskoy terapii u lits s IBS i SD tipa 2 v zavisimosti ot pola / L.A. Nikolenko // Vrach.–12. – S. 54-56.
Rekomendatsii po lecheniyu stabil'noy ishemicheskoy bolezni serdtsa. ESC 2013. (2014) // Rossiyskiy kardiologicheskiy jurnal.– 7 (111). – S. 7-79.
Ryazantseva Ye.Ye. (2014) Yest' li mesto atsetilsalitsilovoy kislote v pervichnoy profilaktike serdechno-sosudistix zabolevaniy: mneniya razdelilis' / Ryazantseva Ye.Ye., Gendlin G.Ye., Melekhov A.V. // Serdtse: jurnal dlya praktikuyushix vrachey. T. 13. № 4 (78). S. 246-255.
Tarasov, A. A. (2010) Medikamentoznaya profilaktika ishemicheskoy bolezni serdtsa [Tekst] : fokus na vospaleniye i endotelial'nuyu disfunktsiyu / A. A. Tarasov, A. R. Babayeva // Lekarstvenniy vestnik.— T. 5, № 7(39). - S. 18-24.-ISSN 2070-1586.
Tanashyan, M.M. (2016) Aspirinorezistentnost': klinicheskiye i molekulyarno-geneticheskiye metodiki otsenki. / M.M. Tanashyan, M.A. Domashenko, A.A. Raskurazhev // Annaly klinicheskoy i eksperimental'noy nevrologii.– Tom 10, № 1. – S. 41-46.
Chubirko, I.Ye. Rezistentnost' trombotsitov k antiagregantam pri lechenii fibrillyatsii predserdiy u bol'nykh ishemicheskoy bolezn'yu serdtsa i khronicheskoy obstruktivnoy bolezn'yu legkix : avtoref. dis. ... kand. med. nauk / I.Ye Chubirko.- 2015– Voronezh, – 23 s.
Shipanova, Ye.V. Agregatsiya trombotsitov i antiagregantniy effekt atsetilsalitsilovoy kisloti u patsiyentov s metabolicheskim sindromom : avtoref. dis. ... kand. med. nauk / Ye.V. Shchipanova.-2015 – Ul'yanovsk, – 24 s.
